BBVA USA’s Core Laboratories CLB Stock Holding History

BBVA USA’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Hold	54	–	–	﹤0.01%	945
2021 Q2	$2K	Buy	+54	New	+$1.94K	﹤0.01%	963

Other funds holding CLB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

BBVA USA's CLB Position: Q3 2021 in Review

BBVA USA held its Core Laboratories (CLB) position steady in Q3 2021 at 54 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #945.

BBVA USA first reported a position in CLB in Q2 2021 and has held it in 2 quarters since. The position peaked at $2K in Q2 2021. 198 funds tracked by Wall St. Rank hold CLB as of Q3 2021.

BBVA USA held 54 shares of Core Laboratories worth $1K as of Q3 2021.
BBVA USA left its Core Laboratories share count unchanged in Q3 2021.
Core Laboratories made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #945 holding.
BBVA USA first reported a position in Core Laboratories in Q2 2021 and has held it in 2 quarters since.
BBVA USA's Core Laboratories position peaked at $2K in Q2 2021.
198 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.